Term ends Feb 2, 2027 · Medium confidence
20-year base term ends Feb 2, 2027
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 7,732,595), so the cap could be lower.
Feb 2, 2007
Feb 2, 2027
Sep 3, 2013
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 2, 2007, when application 11/701,699, the earliest non-provisional in its chain, was filed (this one was filed Dec 21, 2011) | Feb 2, 2027 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,671,192, US 7,732,595, US 8,106,183, US 8,268,988) | resolves to Feb 2, 2027, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 2, 2027 | Medium confidence |
This family
| US 7,732,595 | In force no later than Jul 2027 | no later than Jul 2027 |
| US 7,671,192 | In force Apr 2027 | Apr 2027 |
| US 7,956,179 | In force Feb 2027 | Feb 2027 |
| US 8,106,183 | In force Feb 2027 | Feb 2027 |
| US 8,268,988 | In force Feb 2027 | Feb 2027 |
| US 8,524,883 | this patent Feb 2027 | Feb 2027 |
| US 9,085,601 | Surrendered on reissue Mar 2019 | Mar 2019 |
| US RE47,301 | In force Feb 2027 | Feb 2027 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 6, 2012 Reel 29422, frame 128 | Zablocki, Jeff; Elzein, Elfatih | CV Therapeutics, Inc. | Assignment of Assignor's Interest |
| Dec 6, 2012 Reel 29422, frame 242 | Apex Merger Sub, Inc.; CV Therapeutics, Inc. | Gilead Palo Alto, Inc. | Merger |
| Dec 6, 2012 Reel 29422, frame 265 | Gilead Palo Alto, Inc. | Gilead Sciences, Inc. | Assignment of Assignor's Interest |
| Jan 29, 2013 Reel 29716, frame 839 | Lemons, Travis; Seemayer, Robert | Gilead Sciences, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 7,671,192, US 7,732,595, US 8,106,183, US 8,268,988, ends no earlier than this term, so it caps nothing.